188 related articles for article (PubMed ID: 31012549)
1. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.
Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB
Pediatr Blood Cancer; 2019 Aug; 66(8):e27765. PubMed ID: 31012549
[TBL] [Abstract][Full Text] [Related]
2. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279
[TBL] [Abstract][Full Text] [Related]
3. An Fc-engineered CD19 antibody eradicates MRD in patient-derived
Schewe DM; Alsadeq A; Sattler C; Lenk L; Vogiatzi F; Cario G; Vieth S; Valerius T; Rosskopf S; Meyersieck F; Alten J; Schrappe M; Gramatzki M; Peipp M; Kellner C
Blood; 2017 Sep; 130(13):1543-1552. PubMed ID: 28698205
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB
PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469
[TBL] [Abstract][Full Text] [Related]
5. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
[TBL] [Abstract][Full Text] [Related]
6. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
Meany HJ; Seibel NL; Krailo M; Villaluna D; Chen Z; Gaynon P; Neglia JP; Park JR; Hutchinson R; Sato JK; Wells RJ; Woods WG; Reaman G
J Immunother; 2015 Sep; 38(7):299-305. PubMed ID: 26261894
[TBL] [Abstract][Full Text] [Related]
7. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
[TBL] [Abstract][Full Text] [Related]
8. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
Gerber HP; Kung-Sutherland M; Stone I; Morris-Tilden C; Miyamoto J; McCormick R; Alley SC; Okeley N; Hayes B; Hernandez-Ilizaliturri FJ; McDonagh CF; Carter PJ; Benjamin D; Grewal IS
Blood; 2009 Apr; 113(18):4352-61. PubMed ID: 19147785
[TBL] [Abstract][Full Text] [Related]
9. Belantamab Mafodotin: First Approval.
Markham A
Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
[TBL] [Abstract][Full Text] [Related]
10. Eradication of CD19+ leukemia by targeted calicheamicin θ.
Bernt KM; Prokop A; Huebener N; Gaedicke G; Wrasidlo W; Lode HN
Bioconjug Chem; 2009 Aug; 20(8):1587-94. PubMed ID: 19572629
[TBL] [Abstract][Full Text] [Related]
11. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
[TBL] [Abstract][Full Text] [Related]
12. In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.
Randall J; Evans K; Watts B; Smith CM; Hughes K; Earley EJ; Erickson SW; Pachter JA; Teicher BA; Smith MA; Lock RB
Pediatr Blood Cancer; 2023 Aug; 70(8):e30398. PubMed ID: 37140091
[TBL] [Abstract][Full Text] [Related]
13. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.
Schwemmlein M; Stieglmaier J; Kellner C; Peipp M; Saul D; Oduncu F; Emmerich B; Stockmeyer B; Lang P; Beck JD; Fey GH
Leukemia; 2007 Jul; 21(7):1405-12. PubMed ID: 17495978
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
Ryan MC; Palanca-Wessels MC; Schimpf B; Gordon KA; Kostner H; Meyer B; Yu C; Van Epps HA; Benjamin D
Blood; 2017 Nov; 130(18):2018-2026. PubMed ID: 28903943
[TBL] [Abstract][Full Text] [Related]
15. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
Hicks SW; Tarantelli C; Wilhem A; Gaudio E; Li M; Arribas AJ; Spriano F; Bordone R; Cascione L; Lai KC; Qiu Q; Taborelli M; Rossi D; Stussi G; Zucca E; Stathis A; Sloss CM; Bertoni F
Haematologica; 2019 Aug; 104(8):1633-1639. PubMed ID: 30733273
[TBL] [Abstract][Full Text] [Related]
16. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
[TBL] [Abstract][Full Text] [Related]
17. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
18. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
Farhadfar N; Litzow MR
Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
[TBL] [Abstract][Full Text] [Related]
19. Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia.
Alruwetei AM; Bendak K; Yadav BD; Carol H; Evans K; Mayoh C; Sutton R; Marshall GM; Lock RB
Br J Cancer; 2020 Sep; 123(5):742-751. PubMed ID: 32536690
[TBL] [Abstract][Full Text] [Related]
20. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
